载脂蛋白M与炎症性疾病的相关性研究进展

doi:10.3969/j.issn.1673-8640.2018.03.015

摘要/Abstract

摘要：

载脂蛋白M（apo M）是新近发现的一种载脂蛋白,主要表达于肝脏和肾脏中,受转录因子、细胞因子、激素等多种生物活性分子调控。apo M在多种炎症状态及炎症性疾病中存在异常表达。因此,深入研究apo M的特性、调控及其与炎症性疾病之间的关系将有助于进一步理解和探索相关疾病的发病机制、诊断方法和治疗措施。文章对apo M调控及其与炎症性疾病的相关性研究进展作一综述。

关键词: 载脂蛋白M, 调控, 炎症性疾病

Abstract:

Apolipoprotein M （apo M） is a recently-discovered lipoprotein-associated plasma protein,which is highly expressed in liver and kidney. The expression of apo M is directly regulated by transcription factors,hormones,cytokines and other factors. Abnormal expression of apo M occurs frequently at inflammatory status. Further research on its features,regulation and effects of apo M is needed. The pathogenesis,diagnostic methods and treatment methods should be investigated. This review focuses on the recent research progress of apo M regulation and its relationship with inflammatory diseases.

Key words: Apolipoprotein M, Regulation, Inflammatory disease

中图分类号:

R446.1

高继娟, 方欢英. 载脂蛋白M与炎症性疾病的相关性研究进展[J]. 检验医学, 2018, 33(3): 252-258.

GAO Jijuan, FANG Huanying. Research progress in the relationship of apolipoprotein M with inflammatory diseases[J]. Laboratory Medicine, 2018, 33(3): 252-258.

参考文献 47

1	XU N,DAHLBÄCK B. A novel human apolipoprotein (apoM)[J]. J Biol Chem,1999, 274(44):31286-31290.
2	DAHLBÄCK B,NIELSEN L B. Apolipoprotein M-a novel player in high-density lipoprotein metabolism and atherosclerosis[J]. Curr Opin Lipidol,2006,17(3):291-295.
3	DUAN J,DAHLBÄCK B,VILLOUTREIX B O. Proposed lipocalin fold for apolipoprotein M based on bioinformatics and site-directed mutagenesis[J]. FEBS Lett,2001,499(1-2):127-132.
4	AXLER O,AHNSTRÖM J,DAHLBÄCK B. An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma[J]. J Lipid Res,2007,48(8):1772-1780.
5	胡志高,屈晓冰,胡敏. 载脂蛋白M与冠状动脉病变的关系[J]. 中国动脉硬化杂志,2008,16(3):224-226.
6	史清海,路西春. 载脂蛋白M的生物学特性及其研究进展[J]. 检验医学,2007,22(2):215-216.
7	WOLFRUM C,HOWELL J J,NDUNGO E,et al. Foxa2 activity increases plasma high density lipoprotein levels by regulating apolipoprotein M[J]. J Biol Chem,2008,283(24):16940-16949.
8	胡炎伟. Nur77影响apoE-/-小鼠动脉粥样硬化进展及相关机制研究[D]. 广州:南方医科大学, 2012.
9	任坤,唐振丽,易光辉. 载脂蛋白M[J]. 中国生物化学与分子生物学报,2015,31(6):557-565.
10	梁斌,白瑞,韩耀霞,等. 脂联素经肝X受体α途径对RAW 264.7巨噬细胞ABCG1表达的影响[J]. 生物化学与生物物理进展,2015,42(9):850-857.
11	朱兆金. 肝X受体激动剂T0901317对载脂蛋白M表达的影响[D]. 苏州:苏州大学,2008.
12	赵家仪,胡炎伟,郑磊,等. 二氢辣椒碱通过抑制Foxa2和增强LXRα下调HepG2细胞中ApoM的表达[J]. 中国动脉硬化杂志,2013,21(9):54.
13	VENTECLEF N,HARONITI A,TOUSAINT J J,et al. Regulation of anti-atherogenic apolipoprotein M gene expression by the orphan nuclear receptor LRH-1[J]. J Biol Chem,2008,283(7):3694-3701.
14	HUANG X S,ZHAO S P,HU M,et al. Apolipoprotein M likely extends its anti-atherogenesis via anti-inflammation[J]. Med Hypotheses,2007,69(1):136-140.
15	王敏,罗光华,张晓膺. 载脂蛋白M-1-磷酸鞘氨醇轴与炎症相关性疾病关系的研究进展[J]. 临床检验杂志,2016,34(8):614-617.
16	GALVANI S,SANSON M,BLAHO V A,et al. HDL-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor S1P1 to limit vascular inflammation[J]. Sci Signal,2015,8(389):ra79.
17	RUIZ M,FREJ C,HOLMÉR A,et al. High-density lipoprotein-associated apolipoprotein M limits endothelial inflammation by delivering sphingosine-1-phosphate to the sphingosine-1-phosphate receptor 1[J]. Arterioscler Thromb Vasc Biol,2017,37(1):118-129.
18	GAO J J,HU Y W,WANG Y C,et al. ApoM suppresses TNF-α-induced expression of ICAM-1 and VCAM-1 through inhibiting the activity of NF-κB[J]. DNA Cell Biol,2015, 34(8):550-556.
19	XU N, ZHANG X Y, DONG X, et al. Effects of platelet-activating factor, tumor necrosis factor,and interleukin-1 alpha on the expression of apolipoprotein M in HepG2 cells[J]. Biochem Biophys Res Commun,2002,292(4):944-950.
20	REN K,MO Z C,LIU X,et al. TGF-β down-regulates apolipoprotein M expression through the TAK-1-JNK-c-Jun pathway in HepG2 cells[J]. Lipids,2017,52(2):109-117.
21	SU W,JIAO G,YANG C,et al. Evaluation of apolipoprotein M as a biomarker of coronary artery disease[J]. Clin Biochem,2009,42(4-5):365-370.
22	ZHANG Y,HUANG L Z,YANG Q L,et al. Correlation analysis between ApoM gene-promoter polymorphisms and coronary heart disease[J]. Cardiovasc J Afr,2016,27(4):228-237.
23	LI H,LIU Y,WANG L,et al. High apolipoprotein M serum levels correlate with chronic obstructive pulmonary disease[J]. Lipids Health Dis,2016,15:59.
24	XU N, NILSSON-EHLE P, HURTIG M, et al. Both leptin and leptin-receptor are essential for apolipoprotein M expression in vivo[J]. Biochem Biophysl Res Commun,2004,321(4):916-921.
25	BURKART K M,MANICHAIKUL A,WILK J B,et al. APOM and high-density lipoprotein are associated with lung function and per cent emphysema[J]. Eur Respir J,2014,43(4):1003-1017.
26	WU X,NIU N,BRISMAR K,et al. Apolipoprotein M promoter polymorphisms alter promoter activity and confer the susceptibility to the development of type 1 diabetes[J]. Clin Biochem, 2009,42(1-2):17-21.
27	NIU N,ZHU X,LIU Y,et al. Single nucleotide polymorphisms in the proximal promoter region of apolipoprotein M gene (apo M) confer the susceptibility to development of type 2 diabetes in Han Chinese[J]. Diabetes Metab Res Rev,2007,23(1):21-25.
28	PLOMGAARD P,DULLAART R P,DE VRIES R,et al. Apolipoprotein M predicts pre-beta-HDL formation:studies in type 2 diabetic and nondiabetic subjects[J]. J Intern Med, 2009,266(3):258-267.
29	ZHANG P,GAO J,PU C,et al. Effects of hyperlipidaemia on plasma apolipoprotein M levels in patients with type 2 diabetes mellitus:an independent case-control study[J]. Lipids Health Dis,2016,15(1):158.
30	NOJIRI T,KURANO M,TOKUHARA Y,et al. Modulation of sphingosine-1-phosphate and apolipoprotein M levels in the plasma,liver and kidneys in streptozotocin-induced diabetic mice[J]. J Diabetes Investig,2014,5(6):639-648.
31	ZHENG L,FENG Y,SHI Y,et al. Intralipid decreases apolipoprotein M levels and insulin sensitivity in rats[J]. PLoS One,2014,9(8):e105681.
32	XU N,AHRÉN B,JIANG J,et al. Down-regulation of apolipoprotein M expression is mediated by phosphatidylinositol 3-kinase in HepG2 cells[J]. Biochim Biophys Acta,2006,1761(2):256-260.
33	罗光华. 载脂蛋白M在血糖调控中的应答反应机制及作用[D]. 苏州:苏州大学,2013.
34	CERVIN C,AXLER O,HOLMKVIST J,et al. An investigation of serum concentration of apo M as a potential MODY3 marker using a novel ELISA[J]. J Intern Med, 2010,267(3):316-321.
35	MUGHAL S A,PARK R,NOWAK N,et al. Apolipoprotein M can discriminate HNF1A-MODY from type 1 diabetes[J]. Diabet Med,2013,30(2):246-250.
36	SRECKOVIC I,BIRNER-GRUENBERGER R,BESENBOECK C,et al. Gestational diabetes mellitus modulates neonatal high-density lipoprotein composition and its functional heterogeneity[J]. Biochim Biophys Acta,2014,1841(11):1619-1627.
37	江华,罗光华,张俊,等. 血清载脂蛋白M水平在正常妊娠和妊娠糖尿病孕妇中的变化[J]. 中华内分泌代谢杂志,2014,30(9):727-730.
38	KUMARASWAMY S B,LINDER A,ÅKESSON P,et al. Decreased plasma concentrations of apolipoprotein M in sepsis and systemic inflammatory response syndromes[J]. Crit Care, 2012,16(2):R60.
39	CHRISTOFFERSEN C,NIELSEN L B. Apolipoprotein M-a new biomarker in sepsis[J]. Crit Care,2012,16(3):126.
40	赵婷婷. 载脂蛋白M对细菌性肺炎的诊断和病情严重程度的判断价值[J]. 国际检验医学杂志,2015,37(5):588-590.
41	HU H J,JIN E H,YIM S H,et al. Common variants at the promoter region of the APOM confer a risk of rheumatoid arthritis[J]. Exp Mol Med,2011,43(11):613-621.
42	HUANG Y,LIU Y,JIANG L,et al. Apolipoprotein m (APOM) levels and APOM rs805297 G/T polymorphism are associated with increased risk of rheumatoid arthritis[J]. Joint Bone Spine,2014,81(1):32-36.
43	WANG Z,LUO G,FENG Y,et al. Decreased splenic CD4(+) T-lymphocytes in apolipoprotein M gene deficient mice[J]. Biomed Res Int,2015,2015:293512.
44	FEINGOLD K R,SHIGENAGA J K,CHUI L G,et al. Infection and inflammation decrease apolipoprotein M expression[J]. Atherosclerosis,2008,199(1):19-26.
45	古今刚. 乙型肝炎病毒对血浆载脂蛋白表达影响的研究及其机制探讨[D]. 武汉:武汉大学, 2013.
46	SVARRER E M,ANDERSEN H Ø,HELVIND M,et al. Urinary apolipoprotein M as a biomarker of acute kidney injury in children undergoing heart surgery[J]. Biomark Med,2016,10(1):81-93.
47	XU X L,MAO Q Y,LUO G H,et al. Urinary apolipoprotein M could be used as a biomarker of acute renal injury:an ischemia-reperfusion injury model of kidney in rat[J]. Transplant Proc,2013,45(6):2476-2479.

[1]	孙传玉, 赵晓君, 葛圣阳, 张扬. 前列腺癌进展相关转录因子研究[J]. 检验医学, 2023, 38(9): 818-824.
[2]	费冰, 刘莹, 任彦颖, 郭梦雨, 刘心伟, 刘冬梅, 李永伟. 环二鸟苷酸调控铜绿假单胞菌生物被膜研究进展[J]. 检验医学, 2023, 38(2): 186-189.
[3]	顾玉微, 王成云, 顾萍, 潘秋辉, 王静, 陈广洁. ABO等位基因调控区突变致抗原弱表达原因分析[J]. 检验医学, 2021, 36(6): 637-641.
[4]	王子谨, 张晓膺. 载脂蛋白M在非小细胞肺癌A549细胞增殖、迁移和侵袭中的作用[J]. 检验医学, 2020, 35(9): 937-942.
[5]	章黎华, 王维维, 张良, 沈立松. 单核细胞HLA-DR和CD16检测在炎症性疾病中的应用价值[J]. 检验医学, 2018, 33(9): 775-780.
[6]	吴永琴, 应春妹. 白念珠菌唑类药物相关耐药基因及其调控机制的研究进展[J]. 检验医学, 2016, 31(9): 739-743.
[7]	魏婷婷, 杨敏, 唐晴琴, 仲人前. 长链非编码RNA在免疫炎症反应中的研究进展[J]. 检验医学, 2015, 30(10): 1044-1047.
[8]	李凤综述, 李智审校. miRNA“封闭海绵”的构建与应用[J]. 检验医学, 2014, 29(2): 178-181.
[9]	赵付菊综述，赵虎审校. 染色体介导AmpC β-内酰胺酶表达的分子调控机制的研究进展[J]. 检验医学, 2014, 29(10): 1064-1068.
[10]	龙吟，李智. 转录因子YY1与肿瘤研究进展[J]. 检验医学, 2013, 28(4): 329-332.
[11]	张战锋;黎小琼;黄宪章. 细胞周期蛋白依赖性激酶2及相关蛋白研究进展[J]. 检验医学, 2011, 26(10): 710-713.
[12]	胡敏;黎照环;张彩红. 不同性别人群血清载脂蛋白M与高敏C反应蛋白相关性分析[J]. 检验医学, 2011, 26(02): 75-78.
[13]	吴蓓颖;顾志冬;樊绮诗;倪培华. 血清中TIGAR 的ELISA建立及初步临床试验[J]. 检验医学, 2010, 25(09): 719-722.
[14]	涂婉;赵虎. AmpC β-内酰胺酶的分子生物学研究进展[J]. 检验医学, 2009, 24(11): 845-848.
[15]	李卿;蒋燕群. 可诱导性质粒ampC基因表达的调控[J]. 检验医学, 2009, 24(10): 764-767.